Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Agennix AG

Latest From Agennix AG

Agennix expires

At an extraordinary general meeting (EGM) on 22 May, Agennix shareholders voted in favor of the liquidation of the company. It will be dissolved by 31 May 2013, with liquidation slated to take at least a year following dissolution.

Cardiovascular Cancer

Agennix proposes liquidation

Agennix, which has looked doomed since the failure of its only significant asset last year, is considering two options ahead of an extraordinary general meeting (EGM) on 22 May 2013. It will ask shareholders to vote on two proposals: a 20:1 reverse stock split and liquidiation of the company.

Cardiovascular Cancer

Hopp not wavering but sinking €80m into CureVac

It's not easy to raise large sums of cash for biotech drug development these days, so having software billionaire Dietmar Hopp on side is an enviable position to be in. And despite the recent blow to his portfolio dealt by the late-stage failure of Agennix's talactoferrin (, 7 August 2012), his commitment to biotech is "unwavering", according to one of the key curators of his biotech portfolio, Dr Friedrich von Bohlen. Today's announcement by CureVac would appear to demonstrate this.

Cardiovascular Cancer

Deals Of The Week: Allergan/Molecular Partners, Silence Therapeutics/MiReven, Pfizer/Mylan

The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Agennix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Agennix AG
  • Senior Management
  • Torsten Hombeck, PhD, CFO
    Jill Porter, PhD, SVP, Pharmaceutical Dev.
  • Contact Info
  • Agennix AG
    Phone: (49) 89 85 65 2600
    Im Neuenheimer Feld 515
    Heidelberg, 69120